Corporate Finance
 View our complete news listing.


PharmaForce Acquired by Daiichi-Sankyo

Cross-border deal marks William Blair & Company's 16th transaction in the pharmaceutical industry.


January 12, 2010 - William Blair & Company announces the success of its client, PharmaForce, in connection with its acquisition by Luitpold Pharmaceuticals, a subsidiary of Daiichi-Sankyo Company, Ltd. William Blair & Company acted as exclusive financial advisor to PharmaForce, Inc. for the transaction, the terms of which are not disclosed.

PharmaForce is a U.S.-based specialty injectable pharmaceutical company offering a fully-integrated complement of sterile manufacturing, development, and marketing capabilities. The company maintains a broad portfolio of FDA-approved injectable generic products and a deep pipeline of development candidates. Since receiving its first ANDA approval in July 2002, PharmaForce has received over 40 drug approvals from the FDA with a consistent focus on the development of difficult to develop, first-to-market generic products. Given the recent, well-publicized quality and regulatory issues scarring offshore drug manufacturers, PharmaForce, with its pristine regulatory compliance record, recognized reputation for excellence, and U.S.-based manufacturing operations, is in demand now more than ever as a trusted manufacturer of high quality sterile drug products.

Luitpold Pharmaceuticals, a Daiichi-Sankyo group company headquartered in Shirley, New York, manufactures and distributes over 65 pharmaceutical products along with dental bone regeneration products and veterinary pharmaceuticals through its Osteohealth and Animal Health divisions. Daiichi-Sankyo, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator with annual revenues of nearly $10 billion.

PharmaForce engaged William Blair & Company in May 2009 to conduct a sale of the company. PharmaForce and the William Blair & Company investment banking team launched a targeted marketing process, focusing primarily on strategic parties in the United States, Europe, and Asia. In connection with the engagement, William Blair & Company developed a confidential descriptive memorandum, created a management presentation, coordinated the due diligence process, and negotiated key terms of the definitive agreement.

Healthcare Investment Banking

Back to top

Media Relations Contact:
Tony Zimmer, 312-364-8611

Subscribe to News Alerts
Statement of Financial Condition | NMS Rule 605 and Rule 606 Information | Site Map | Privacy and Security
Copyright © 2010 William Blair & Company, L.L.C.
"William Blair & Company", "William Blair & Company (script)", "R*Docs", and "A Tradition of Growth" are registered trademarks of William Blair & Company, L.L.C.
This site and the content accessible herein are subject to certain disclaimers.